TriSalus Life Sciences Inc (TLSI) News

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

– New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of...

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

– New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of a...

TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics

Devlin Brings Significant Expertise in Commercialization, Sales and Marketing TriSalus Life Sciences® Inc., (TriSalus or the Company), an...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form SC 13D - General statement of acquisition of beneficial ownership

Form 8-K - Current report